Principles of tumour immunology
|
|
- Nathan Baker
- 5 years ago
- Views:
Transcription
1 Principles of tumour immunology Michele Teng Nov 20 th 2017, Singapore Cancer Immunoregulation and Immunotherapy Laboratory QIMR Berghofer MRI Brisbane, Australia
2 Disclosure Slide I have received speakers bureau honoria from Merck Sharp & Dohme.
3 Talk Outline 1. Hallmarks of Cancer 2. Cells of the Immune system 3. The Cancer Immunity Cycle - Tumor-associated antigens (TAA), Cellular and Humoral responses to TAA 4. Conceptual developments in the field of tumour immunology - Immunosurveillance and role of innate immunity, immune balance against cancer
4 Sources of slide Charles Janeway s Immunobiology text book Peer-reviewed articles (Pubmed) Online slides ( URL listed)
5 Cancer
6 Hallmarks of Cancer (2000) Hanahan and Weinberg, Cell 2000
7 Emerging Hallmarks and Enabling Characteristics Hanahan and Weinberg, Cell 2011
8 Hallmarks of Cancer (2017) In Vitrogen
9 Immunology (Study of the immune system)
10 Cells of the immune system ILCs innate lymphoid cells MAITs Mucosal associated invariant T cells gd T cells gamma delta T cells (ILCs) (gd, MAIT)
11 Cancer Immunology (Study of the response of the immune system to cancer)
12 The Cancer-Immunity Cycle Steps to generate an effective anti-tumour response Chen and Mellman Immunity 2013
13 Not all cell deaths are equal (at priming an immune response)
14 Cells can die in different ways DAMPs Tumour fragments Immunogenic Cell Death (ICD) (Adjuvanticity, Antigenicity) DAMPs Damage associated molecular patterns
15 Differential requirements for the immunogenicity of cell death TLR4 Nat Rev Immunol Feb;17(2): doi: /nri
16 The Cancer-Immunity Cycle Immunity Jul 25;39(1):1-10. doi: /j.immuni
17 Types of professional Antigen Presenting Cells (APCs) Nat Rev Immunol Nov;14(11): doi: /nri3754.
18 Activation of tumour-specific T cells by APCs TCR with the right specificity
19 Tumor-specific and tumor-associated antigens (Neoantigens) QIMR Berghofer Medical Research Institute 19
20
21 TAA therapeutic targets?
22 Cell-mediated and humoral immune responses to tumour
23 Requirements for effective priming of T cells Front. Oncol., 10 April
24 The many flavours of CD4 + T cells Th22
25 Cell-mediated and humoral immune responses to tumour
26 T cell-independent and T cell-dependent B cell activation
27 Antibody mechanism of action IgG1 FcgRIIIa -activating receptor NK cells
28 Antibody mechanism of action Activate cellular effector function Antibody-Dependent Cell-Mediated Cytotoxicity Antibody-Dependent Cellular Phagocytosis Biolegend
29 ADCC - the underlying mechanism for the clinical efficacy of therapeutic anti-cancer antibodies. Biolegend
30 Effector responses of NK cells are regulated by inhibitory and activatory receptors Release of Cytokines Cytolysis Trends in Immunology , DOI: ( /j.it )
31 Major inhibitory and activating receptors on NK cells and their cognate ligands on targets NKp30 isoforms predict clinical outcome of GIST, neuroblastoma Chan et al., 2014 Cell Death Differentiation
32 The Cancer-Immunity Cycle Immunity Jul 25;39(1):1-10. doi: /j.immuni
33 When the Cancer Immunity Cycle is successfully completed
34 Cancer Immunology (pre 2000) Reason for failures Cancer Immunology ( ) - What went right...
35 Conceptual Developments in Cancer Immunology 2 Tumour Neoantigen 1 Cancer immunoediting 3 Immune Reaction 4 Combination mab-based therapy 5 Tumour induced Immune suppression
36 1 3Es KILL BATTLE LOSE Smyth et al. JEM 2000, Shankaran et al. Nature 2001 Swann et al. J. Clin. Invest. 2007, Koebel et al. Nature 2007 Teng et al., JLB 2008; Schreiber..Smyth. Science 2011 Teng et al., Cancer Res QIMR 2012, Berghofer Teng Medical et al., Research JCI 2015 Institute 36
37 2 Mutational load correlates with frequency of tumour neoantigens... & response Estimate of the neoantigen repertoire in human cancer Synder A et al., NEJM 2014 van Allen et al., Science, 2015, Hugo W et al., Cell 2016 Ton N. Schumacher, and Robert D. Schreiber Science 2015;348:69-74 MHC Quality
38 3 Immune contexture correlates with clinical outcome NKT Stroma Immune contexture associated with good prognosis in CRC Chemokine CXCL9 CX3CL1 CXCL10 CCL2 CCL5 CXCL13 Adhesion MADCAM1 ICAM1 VCAM1 Cytotoxic Granzymes Perforin Granulysin Eosinophil Immature DC NK Neutrophil DC Blood vesse l T H 1 Mast cell Tumor core Lymphaic vessel B cells CTL T H 17 MDSC Treg Macrophage Invasive margin Location, density, functional orientation of cells γδt F-DC T FH T H 1 T-bet IRF1 STAT1 T H 1 IL-12 IFN-γ IL-15 T H 1 Epithelial/smooth muscle layer TLS T FH IL21 B cells Tumor margin CD3+, CD8+, CD45RO+ T cells Immunoscore Galon et al., 2006 Science, Pages et al., 2005 NEJM, Fridman et al., 2012 NRC, Bindea el al., 2013 Immunity
39 Mechanism of Treg mediated immunosuppression Worman C et al., Cell Mol Life Sci 2009
40 Mechanism of MDSC mediated immunosuppression Dmitry I. Gabrilovich Cancer Immunol Res 2017;5:3-8
41 4 (trimab) trimab anti-dr5 (immunogenic cell death) anti-cd40 (activate APC) anti-cd137 (enhance effector T cell function and survival) MCA induced fibrosarcoma model MCA WT or KO mouse d Detect sarcoma Measure growth Commence treatment
42 Rejection of carcinogen-induced established tumors by trimab Uno et al. Nature Medicine, 2006
43 4 The four nodes to target for inducing maximal anti-tumour immunity Smyth et al., NRCO 2016
44 5 Engagement of checkpoint receptors represents a major mechanism of tumour-induced immunosuppression Checkpoint receptors: Brakes to limit overzealous T cell activation About 20 interactions regulate T cell immune response APC/Tumour T cell Melero I et al. Nat Rev Cancer 2015
45 Checkpoint blockade can unleash endogenous anti-tumour response ORR 10% 2010 ORR 31% 2012 ORR 53% 2013 ORR 61% 2015
46 Anti-PD-1 to be used as standard of care and in combination immunotherapies ORR 33.7% vs 11.9% 2015 ORR 31.7% vs 10.6% 2015 ORR 20% vs 9% 2015 ORR 44.8% vs 27.8% 2016
47 Cancer immunotherapy-based combination studies underway in 2016 Chen & Mellman Nature 2017
48 Tumour microenvironment can be stratified into 4 types based on TILs and PD-L1 expression in tumours Teng et al., 2015 Cancer Res
49 Summary Anti-PD-1/PD-L1 - will become the immunotherapeutic backbone of future cancer treatments Cancers can be divided into four type absence or presence of TILs and PD-L1 expression Efficient anti-tumour strategies must focus on hitting different targets concurrently Key nodes to target in combination treatment abrogating immune suppression inducing immunogenic cancer-cell death, enhancing antigen presentation/adjuvanticity inducing activation and survival of immune-effector cells
50 Summary Exome-sequencing data can be mined to identify unique neoantigen profile of tumours guide future personalized vaccine design for use in combination treatments A large proportion of patients have immune ignorant (cold) tumours, predicted to have a poor prognosis regardless of any current intervention novel therapies have to be developed (Oncolytic virus, STING agonist, CAR-T).
51 Moving Forward
52 Key issues in cancer immunotherapy 1) Identifying biomarkers to predict what cancers and pts will respond to anti-pd-1/pd-l1 2) How do we increase the proportion of patients who respond to anti-pd-1/pd-l1? 3) What therapies do we use to treat cancers with microenvironments that are resistant to anti-pd-1/pd- L1 monotherapy? 4) What do we do for patients who develop acquired resistance to anti-pd-1 therapies? 5) What is the optimal scheduling for administration of combination immunotherapy? 6) How to assess the therapeutic index (anti-tumour efficacy/iraes) of combination immunotherapies?
53 Overall Survival Improving the tail of the curve... Time
54 Thank You
55 Identifying biomarkers to predict patients who will respond to anti-pd-1/pd-l1
56 Tumour microenvironment can be stratified into 4 types based on TILs and PD-L1 expression in tumours TIL + PD-L1 + (38%) Type I TIL - PD-L1 - (41%) Type II Melanoma Type IV TIL + PD-L1 - (20%) Type III TIL - PD-L1 + (1%) Taube et al. Sci Transl Med 2012, CCR 2014
57 Association of anti-pd-l1 response and tumour-infiltrating immune cell PD-L1 expression Nature, 2014
58 Cancers with type I TME containing CD8 + T cells and PD-L1 most likely to respond to anti-pd-1/pd-l1 Level of PD-1 expression Ngiow et al., Cancer Res 2015 PDL2 expression? Tumeh et al. Nature (2014)
59 QIMR Berghofer Medical Research Institute 59
60 Factors that influence the cancer immune set point
61 Biomarkers of response to PD-1/PDL1 blockade Angiogenesis Density, Location PD-1 expression level Other checkpoint receptors Epigenetics Other immune cells MMR-deficient/MSI-H Somatic vs Driver mutations (e.g Braf V600 ) Genetics Mutational Burden CD8 + T cell PD-L1 expressio n Time Durability of Response Tumor/Immune cells IFN gene signature (early on txt) Tumor load Microbiome Age External factors Prior therapy
62 From bed-side To bed-side Clinical research Ex vivo/ In vitro research To bench Experimental Mouse research From bench QIMR Berghofer Medical Research Institute 62
63 Immunotherapy and GI cancer Melero I et al., Abstract presented at: 2017 Gastrointestinal Cancers Symposium; January 19-21, 2017; San Francisco, CA.
64 Atezolizumab (anti-pd-l1) Tecentriq, approved for treatment of bladder cancer
65 Adaptive immune gene signature in early-ontreatment samples best predict responders Checkpoint immunotherapy: picking a winner Teng et al., Cancer Discovery 2016 in press Chen, P, Cancer Discov, 2016 EDT median 1.4 months ( months) Vilain et al EJC 2015; EDT (within 2 months of treatment) increase in intratumoral CD3+, CD8+, CD68+ in responders Non-responders increased VEGFA
66 How do we increase the proportion of patients who respond to anti-pd-1/pd-l1?
67 Can we improve above the 50% ORR induced by anti-ctla-4 & anti-pd-1? * *Without the toxicity
68 Combination of anti-pd-1 or anti-ctla-4 with IDO inhibitors (Indoximod) in melanoma Abstract #3075 ASCO 2016, Yousef Zakharia.. Mhd Milhem
69 IDO - Indoleamine 2,3-dioxygenase, an immune suppressor Abstract #3075 ASCO 2016, Yousef Zakharia.. Mhd Milhem
70 ORR 53% No increase in toxicity Phase II trial ongoing 64 pts Questions 1) PFS? 2) Durability 3) Other cancers?
71 What therapies do we use to treat cancers with TME that are resistant to anti-pd-1/pd-l1 monotherapy?
72 T-VEC + anti-ctla-4 Chemotherapy or targeted therapy + anti-pd-1 Radiotherapy + anti-ctla-4 + anti- PD-1(Twyman-Saint Victor et al., Nature 2015) Type I IFN (poly-ic) + anti-pd-1 (Bald et al. Cancer Discovery 2014) Microbiota (Zitvogel L et al, Gajewski T el, Science 2015) Engineering FcR engaging variants of IgG (Ravetch Cancer Cell 2016) Scheduling (Neoadjuvant/adjuvant) CAR-T + anti-pd-1 anti-cd40 + anti-il-23 anti-cd40 + anti-csfr1
73 What other cancers should we treat with anti-pd-1/pd-l1?
74 PD-1 & PD-L1 expression in various types of solid tumours
75 PD-1 + TILs expression correlates with increasing mutational load Le et al., NEJM, 2015; Maby et al., Cancer Res, 2015
76
77 Gut bacteria affect immunotherapy effectiveness Sivan A et al., Science 2015 Vétizou M et al., Science 2015 The composition of intestinal microbiota affects checkpoint blockade efficacy and can be manipulated to improve responses. Alexandra Snyder et al. Science 2015;350:
78 Neoantigen presentation in the tumour microenvironment Khalil, D. N. et al. (2016) Nat. Rev. Clin. Oncol.
79 T-cell inflamed phenotype gene expression signatures to predict clinical benefit from pembrolizumab across 5 cancer types
80 Biomarkers and response to pembrolizumab (pembro) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)
81 What do we do for patients who develop acquired resistance to anti-pd-1 therapies?
82 Jesse Zaretsky.. Antoni Ribas NEJM 2016 Mean time to relapse 624 days (range, 419 to 888)
83 Mechanisms of resistance Whole-exome sequencing of biopsy samples fomr paired baseline and relapsing lesions in 4 pts 2 pts; IFNgR associated JAK1/JAK2 mutations loss of ability to respond to IFNg 1 pt; b2m mutation loss of surface MHC I expression 1 pt; - no defined genetic alterations to explain acquired resistance (no PDL1 on tumors pre/post txt)
84 Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma Hugo W,.. Ribas A, Lo R Cell 2016
85 Association of PD-L2 expression in human tumors with atezolizumab activity. QIMR Berghofer Medical Research Institute 85
86 QIMR Berghofer Medical Research Institute 86
87 QIMR Berghofer Medical Research Institute 87
88 QIMR Berghofer Medical Research Institute 88
89 Evidence for immunoediting in human tumours Analysis of 18 TCGA tumour types shows genomic correlates of immune cytolytic activity Multiple tumour types demonstrate strong link between mutation load and local immunity Number of predicted MHC Class I- associated neoantigens correlated with cytolytic activity. Lower than expected in colorectal and other tumours, suggesting immune-mediated elimination Rooney et al., Cell 2015 Infiltrated tumours are enriched for probable escape lesions affecting CASP8, HLA, B2M
90 Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability MSI and a subgroup of MSS patients have high intratumoral adaptive immune gene expression Functional effector anti-frameshift mutation CTLs kill tumor cells in MSI patients Genetic evidence of immunoediting in human CRC, in particular for MSI patients Mlecnik et al., Immunity 2016 Immunoscore gives an indicator of tumor recurrence and survival beyond MSI staging
91 QIMR Berghofer Medical Research Institute 91
92 Tumor associated antigens and tumor specific antigens
93 ecancer /
94 Activation of tumor specific T cells by Antigen Presenting Cells (APCs)
95 Antibody mechanism of action QIMR Berghofer Medical Research Institute 95
96
97
98 Targeting CTLA-4 and PD-1 to release the brakes on T cells Lymph Node "inflammatory site (tumor) Ribas A NEJM 2012
99 The Immune System Delves P and Roitt I, NEJM 2000
100 Targeting NK cells in cancer immunotherapy Guillerey C et al., Nat Immunol 2016
Innovation in Prevention, Early Detection & Diagnosis of Colorectal Cancer Heidelberg Workshop Session VI, Oncology Pipeline June 6, 2014
Innovation in Prevention, Early Detection & Diagnosis of Colorectal Cancer Heidelberg Workshop Session VI, Oncology Pipeline June 6, 2014 Bernd Mueller MSD Sharp & Dohme, Germany Normal Immune Surveillance:
More informationMolecular mechanisms of the T cellinflamed tumor microenvironment: Implications for cancer immunotherapy
Molecular mechanisms of the T cellinflamed tumor microenvironment: Implications for cancer immunotherapy Thomas F. Gajewski, M.D., Ph.D. Professor, Departments of Pathology and Medicine Program Leader,
More informationEmerging Tissue and Serum Markers
Emerging Tissue and Serum Markers for Immune Checkpoint Inhibitors Kyong Hwa Park MD, PhD Medical Oncology Korea University College of Medicine Contents Immune checkpoint inhibitors in clinical practice
More informationBiomarkers in Imunotherapy: RNA Signatures as predictive biomarker
Biomarkers in Imunotherapy: RNA Signatures as predictive biomarker Joan Carles, MD PhD Director GU, CNS and Sarcoma Program Department of Medical Oncology Vall d'hebron University Hospital Outline Introduction
More informationTumor Immunity and Immunotherapy. Andrew Lichtman M.D., Ph.D. Brigham and Women s Hospital Harvard Medical School
Tumor Immunity and Immunotherapy Andrew Lichtman M.D., Ph.D. Brigham and Women s Hospital Harvard Medical School Lecture Outline Evidence for tumor immunity Types of tumor antigens Generation of anti-tumor
More informationCancer immunity and immunotherapy. General principles
1 Cancer immunity and immunotherapy Abul K. Abbas UCSF General principles 2 The immune system recognizes and reacts against cancers The immune response against tumors is often dominated by regulation or
More information5% of patients with genetic immunodeficiency develop a cancer during their lifetime (200x)
Immune surveillance 5% of patients with genetic immunodeficiency develop a cancer during their lifetime (200x) Transplanted patients following an immunosuppressor therapy are 80 times more likely to develop
More informationImmunotherapy, an exciting era!!
Immunotherapy, an exciting era!! Yousef Zakharia MD University of Iowa and Holden Comprehensive Cancer Center Alliance Meeting, Chicago November 2016 Presentation Objectives l General approach to immunotherapy
More informationThe PD-1 pathway of T cell exhaustion
The PD-1 pathway of T cell exhaustion SAMO 18.3.2016 Overview T cell exhaustion Biology of PD-1 Mechanism Ligands expressed on tumor cell and on non-tumor cells other receptor pairs Biomarkers for apd-1/pd-l1
More informationImmunotherapy in Colorectal cancer
Immunotherapy in Colorectal cancer Ahmed Zakari, MD Associate Professor University of Central Florida, College of Medicine Medical Director, Gastro Intestinal Cancer Program Florida Hospital Cancer Institute
More informationDarwinian selection and Newtonian physics wrapped up in systems biology
Darwinian selection and Newtonian physics wrapped up in systems biology Concept published in 1957* by Macfarland Burnet (1960 Nobel Laureate for the theory of induced immune tolerance, leading to solid
More informationBasic Principles of Tumor Immunotherapy. Ryan J. Sullivan, M.D. Massachusetts General Hospital Cancer Center Boston, MA
Basic Principles of Tumor Immunotherapy Ryan J. Sullivan, M.D. Massachusetts General Hospital Cancer Center Boston, MA Disclosures Consulting Fees: Biodesix, Novartis Pharmaceuticals Other: Boehringer
More informationIMMUNOTHERAPY FOR CANCER A NEW HORIZON. Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust
IMMUNOTHERAPY FOR CANCER A NEW HORIZON Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust ASCO Names Advance of the Year: Cancer Immunotherapy No recent
More informationNews from ASCO. Niven Mehra, Medical Oncologist. Radboud UMC Institute of Cancer Research and The Royal Marsden Hospital
News from ASCO Niven Mehra, Medical Oncologist Radboud UMC Institute of Cancer Research and The Royal Marsden Hospital Disclosures Speaker fees: Merck, Bayer Advisory boards: Janssen-Cilag Research and
More informationPD-L1 and Immunotherapy of GI cancers: What do you need to know
None. PD-L1 and Immunotherapy of GI cancers: What do you need to know Rondell P. Graham September 3, 2017 2017 MFMER slide-2 Disclosure No conflicts of interest to disclose 2017 MFMER slide-3 Objectives
More informationDisclosure Information. Mary L. Disis
Disclosure Information Mary L. Disis I have the following financial relationships to disclose: Consultant for: VentiRx, Celgene, Emergent, EMD Serono Speaker s Bureau for: N/A Grant/Research support from:
More informationIMMUNOTHERAPY IN THE TREATMENT OF CERVIX CANCER
Gynecologic Cancer InterGroup Cervix Cancer Research Network IMMUNOTHERAPY IN THE TREATMENT OF CERVIX CANCER Linda Mileshkin, Medical Oncologist Peter MacCallum Cancer Centre, Melbourne Australia Cervix
More informationIMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS
IMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS Dr Elizabeth Smyth Cambridge University Hospitals NHS Foundation Trust ESMO Gastric Cancer Preceptorship Valencia 2018 DISCLOSURES Honoraria for advisory role
More informationTumor Microenvironment and Immune Suppression
Tumor Microenvironment and Immune Suppression Hassane M. Zarour,, MD Department of Medicine, Division of Hematology-Oncology, University of Pittsburgh Cancer Institute Hallmarks of Cancer: The Next Generation
More informationManipulating the Tumor Environment
Manipulating the Tumor Environment Vincenzo Bronte Verona University Hospital vincenzo.bronte@univr.it Escape from immune control can be viewed as one of the «Hallmarks of Cancer» D. Hanahan and R. A.
More informationLicia Rivoltini, MD Unit of Immunotherapy of Human Tumors
Licia Rivoltini, MD Unit of Immunotherapy of Human Tumors The complex network of anti-tumor immunity Innate immunity First line defense Tumor cell Adaptive immunity Specificity & memory Kidd et al., Nature
More informationTHE FUTURE OF IMMUNOTHERAPY IN COLORECTAL CANCER. Prof. Dr. Hans Prenen, MD, PhD Oncology Department University Hospital Antwerp, Belgium
THE FUTURE OF IMMUNOTHERAPY IN COLORECTAL CANCER Prof. Dr. Hans Prenen, MD, PhD Oncology Department University Hospital Antwerp, Belgium DISCLAIMER Please note: The views expressed within this presentation
More informationDISCLOSURES. Roche/MSD-Merck/Celgene: Research Funding
DISCLOSURES Roche/MSD-Merck/Celgene: Research Funding Roche/Celgene/AstraZeneca/Amgen/MSD/Novartis/Sanofi- Aventis/Pierre Fabré: Advisory Board or Consultant No conflict of interest with respect to this
More informationBasic Principles of Tumor Immunotherapy and Mechanisms of Tumor Immune Suppression. Bryon Johnson, PhD
Basic Principles of Tumor Immunotherapy and Mechanisms of Tumor Immune Suppression Bryon Johnson, PhD Disclosures There will be discussion about the use of products for non-fda indications in this presentation.
More informationRole of the Pathologist in Guiding Immuno-oncological Therapies. Scott Rodig MD, PhD
Role of the Pathologist in Guiding Immuno-oncological Therapies Scott Rodig MD, PhD Department of Pathology, Brigham & Women s Hospital Center for Immuno-Oncology, Dana-Farber Cancer Institute Associate
More informationRegulation of anti-tumor immunity through migration of immune cell subsets within the tumor microenvironment Thomas F. Gajewski, M.D., Ph.D.
Regulation of anti-tumor immunity through migration of immune cell subsets within the tumor microenvironment Thomas F. Gajewski, M.D., Ph.D. Professor, Departments of Pathology and Medicine Program Leader,
More informationImmunotherapy for the Treatment of Melanoma. Marlana Orloff, MD Thomas Jefferson University Hospital
Immunotherapy for the Treatment of Melanoma Marlana Orloff, MD Thomas Jefferson University Hospital Disclosures Immunocore and Castle Biosciences, Consulting Fees I will be discussing non-fda approved
More informationImmunotherapy of HNC: immune mechanisms and therapeutic targets
Immunotherapy of HNC: immune mechanisms and therapeutic targets Ourania Tsitsilonis, MD, PhD Department of Biology National & Kapodistrian University of Athens What does the Immune System see in Cancer?
More informationFrom mice to humans: developments in cancer immunoediting
From mice to humans: developments in cancer immunoediting Michele W.L. Teng,, Wolf-Herman Fridman, Mark J. Smyth J Clin Invest. 2015;125(9):3338-3346. https://doi.org/10.1172/jci80004. Review Series Cancer
More informationColorectal Cancer in 2017: From Biology to the Clinics. Rodrigo Dienstmann
Colorectal Cancer in 2017: From Biology to the Clinics Rodrigo Dienstmann MOLECULAR CLASSIFICATION Tumor cell Immune cell Tumor microenvironment Stromal cell MOLECULAR CLASSIFICATION Biomarker Tumor cell
More information2/16/2018. The Immune System and Cancer. Fatal Melanoma Transferred in a Donated Kidney 16 years after Melanoma Surgery
C007: Immunology of Melanoma: Mechanisms of Immune Therapies Delphine J. Lee, MD, PhD Chief and Program Director, Dermatology, Harbor UCLA Medical Center Principal Investigator, Los Angeles Biomedical
More informationBiomarkers for immunotherapy. John Haanen MD PhD
Biomarkers for immunotherapy John Haanen MD PhD Clear value of mobilizing endogenous tumor-specific T cell responses 1. TIL therapy J. Haanen, NKI-AVL 1. Checkpoint blockade C. Robert, NEJM 2015 Where
More informationImmunotherapie: algemene principes
Immunotherapie: algemene principes Prof. dr. Evelien Smits Tumorimmunologie, UAntwerpen 14 Oktober 2017, IKG evelien.smits@uza.be Concept of immune evasion Finn O. J. Ann Oncol. 2012 Sep; 23(Suppl 8):
More informationBASIC MECHANISM OF TUMOR IMMUNE SUPPRESSION
BASIC MECHANISM OF TUMOR IMMUNE SUPPRESSION Zihai Li, M.D., Ph.D. Leader, Cancer Immunology Program Hollings Cancer Center Medical University of South Carolina (MUSC) DISCLOSURE GOALS Understand that immune
More informationFocus on Immunotherapy as a Targeted Therapy. Brad Nelson, PhD BC Cancer, Victoria, Canada FPON, Oct
Focus on Immunotherapy as a Targeted Therapy Brad Nelson, PhD BC Cancer, Victoria, Canada FPON, Oct 18 2018 Disclosures I have nothing to disclose that is relevant to this presentation. Immunology @ Deeley
More informationClinical Need and diagnostic challenge-the upcoming landscape of checkpointinhibitors
Clinical Need and diagnostic challenge-the upcoming landscape of checkpointinhibitors ESP/ESMO Marina Chiara GARASSINO Amsterdam 2017 September, 4th 29 European Congress of Pathology Disclosures BMS ROCHE
More informationPriming the Immune System to Kill Cancer and Reverse Tolerance. Dr. Diwakar Davar Assistant Professor, Melanoma and Phase I Therapeutics
Priming the Immune System to Kill Cancer and Reverse Tolerance Dr. Diwakar Davar Assistant Professor, Melanoma and Phase I Therapeutics Learning Objectives Describe the role of the immune system in cancer
More informationBasics of Immuno-Oncology
Basics of Immuno-Oncology 2016. 6. 25 Kyong Hwa Park MD, PhD Oncology/Hematology Korea University Hospital Contents Immune microenvironment in cancer Immunologic therapeutics in Oncology - Cytokines -
More informationImmunotherapeutic barriers at the level of the tumor microenvironment Thomas F. Gajewski, M.D., Ph.D.
Immunotherapeutic barriers at the level of the tumor microenvironment Thomas F. Gajewski, M.D., Ph.D. Professor, Departments of Pathology and Medicine Program Leader, Immunology and Cancer Program of the
More informationImmunotherapy: The Newest Treatment Route
Immunotherapy: The Newest Treatment Route IWMF Patient Forum, Phoenix, AZ Madhav Dhodapkar, MD Professor of Medicine and Immunobiology Chief, Section of Hematology Yale University or the Oldest William
More informationFrédéric Triebel MD, PhD World Immunotherapy Congress Basel, October 30, 2018
Two ACTive immunotherapies in melanoma (TACTI-mel): results of a phase I trial combining a soluble LAG-3 receptor (Eftilagimod Alpha) with Pembrolizumab Frédéric Triebel MD, PhD World Immunotherapy Congress
More informationEmerging immune biomarkers. Athanasios Kotsakis MD, PhD Ast. Professor of Medical Oncology School of Medicine, University of Crete
Emerging immune biomarkers Athanasios Kotsakis MD, PhD Ast. Professor of Medical Oncology School of Medicine, University of Crete Disclosure: none Cancer Immunotherapy Immunotherapy, mainly anti PD 1/PD
More informationNew biomarkers for response to immunotherapy
WIN Paris, 14:15-14:40, June 26, 2017 New biomarkers for response to immunotherapy Antoni Ribas, M.D., Ph.D. Professor of Medicine, Surgery, Molecular and Medical Pharmacology Director, Tumor Immunology
More informationImmune Checkpoints. PD Dr med. Alessandra Curioni-Fontecedro Department of Hematology and Oncology Cancer Center Zurich University Hospital Zurich
Immune Checkpoints PD Dr med. Alessandra Curioni-Fontecedro Department of Hematology and Oncology Cancer Center Zurich University Hospital Zurich Activation of T cells requires co-stimulation Science 3
More informationRespuesta inmune anti-tumoral. Aura Muntasell Institut Hospital del Mar d Investigacions Mèdiques Parc de Recerca Biomèdica de Barcelona
Respuesta inmune anti-tumoral Aura Muntasell Institut Hospital del Mar d Investigacions Mèdiques Parc de Recerca Biomèdica de Barcelona CANCER IMMUNOEDITING Zitvogel et al Nat Rev Immunol (2006) Evidences
More informationImmunotherapeutic barriers at the level of the tumor microenvironment Thomas F. Gajewski, M.D., Ph.D.
Immunotherapeutic barriers at the level of the tumor microenvironment Thomas F. Gajewski, M.D., Ph.D. Professor, Departments of Pathology and Medicine Program Leader, Immunology and Cancer Program of the
More informationMerck Oncology Overview. The Development of MSI-H Cancer Therapy. Development of Anti-Cancer Drugs Forum Tokyo, Japan, 18, February 2017
Merck Oncology Overview The Development of MSI-H Cancer Therapy Development of Anti-Cancer Drugs Forum Tokyo, Japan, 18, February 217 Andrew Joe, MD Executive Director, Late Stage Oncology Merck & Co.,
More informationImmunotherapy for dmmr metastatic colorectal cancer. Prof.dr. Kees Punt Dept. Medical Oncology AUMC
Immunotherapy for dmmr metastatic colorectal cancer Prof.dr. Kees Punt Dept. Medical Oncology AUMC Active specific immunotherapy (ASI) in stage II-III colon cancer Vaccination with autologous tumor + BCG
More informationImmunotherapy in lung cancer. Saurabh maji
Immunotherapy in lung cancer Saurabh maji Worldwide, lung cancer is the most common cause of cancerrelated deaths Small cell lung cancer (SCLC) presents with widespread disease at the time of diagnosis,
More informationCONSIDERATIONS IN DEVELOPMENT OF PEMBROLIZUMAB IN MSI-H CANCERS
CONSIDERATIONS IN DEVELOPMENT OF PEMBROLIZUMAB IN MSI-H CANCERS December 2017 Christine K. Gause, Ph.D Executive Director, Biostatistics. 2 Microsatellite Instability-High Cancer - USPI KEYTRUDA is indicated
More informationGeneral Overview of Immunology. Kimberly S. Schluns, Ph.D. Associate Professor Department of Immunology UT MD Anderson Cancer Center
General Overview of Immunology Kimberly S. Schluns, Ph.D. Associate Professor Department of Immunology UT MD Anderson Cancer Center Objectives Describe differences between innate and adaptive immune responses
More informationIMMUNOTHERAPY IN THE TREATMENT OF CERVIX CANCER. Linda Mileshkin, Medical Oncologist Peter MacCallum Cancer Centre, Melbourne Australia
IMMUNOTHERAPY IN THE TREATMENT OF CERVIX CANCER Linda Mileshkin, Medical Oncologist Peter MacCallum Cancer Centre, Melbourne Australia Distinguishing self from non-self T cells trained in the thymus as
More informationCombining ADCs with Immuno-Oncology Agents
Combining ADCs with Immuno-Oncology Agents Chad May, PhD Senior Director Targeted Immunotherapy Oncology Research Unit, Pfizer 7 th Annual World ADC October 10, 2016 Cancer-Immunity Cycle Innate Immunity
More informationRadiation Therapy as an Immunomodulator
Radiation Therapy as an Immunomodulator Yvonne Mowery, MD, PhD February 20, 2017 Tumor/Immune System Balance Kalbasi, JCI 2013 UNC-Duke-NC State-Wake Forest Spring 2017 2 RT Can Shift Balance Toward Elimination
More informationImmuno-Oncology Clinical Trials Update: Therapeutic Anti-Cancer Vaccines Issue 7 April 2017
Delivering a Competitive Intelligence Advantage Immuno-Oncology Clinical Trials Update: Therapeutic Anti-Cancer Vaccines Issue 7 April 2017 Immuno-Oncology CLINICAL TRIALS UPDATE The goal of this MONTHLY
More informationCancer and the Immune System
NIFA Neue Impulse in Fortbildung und Ausbildung, AstraZeneca Onkologie Symposium, Vienna, October 20 th 2017 Cancer and the Immune System Translational Tumor Immunology Group, Ludwig Cancer Research Center
More informationImmunotherapy for Breast Cancer. Aurelio B. Castrellon Medical Oncology Memorial Healthcare System
Immunotherapy for Breast Cancer Aurelio B. Castrellon Medical Oncology Memorial Healthcare System Conflicts Research support : Cascadian therapeutics, Puma biotechnology, Odonate therapeutics, Pfizer,
More informationImmuno-Oncology Therapies and Precision Medicine: Personal Tumor-Specific Neoantigen Prediction by Machine Learning
Immuno-Oncology Therapies and Precision Medicine: Personal Tumor-Specific Neoantigen Prediction by Machine Learning Yi-Hsiang Hsu, MD, SCD Sep 16, 2017 yihsianghsu@hsl.harvard.edu HSL GeneticEpi Center,
More informationDisclosures. Immunotherapyin Head & NeckCancer. Actual landscape of systemic treatment in HNSCC. Head andneckcanceris an immunogeneic tumor
Immunotherapyin Head & NeckCancer Disclosures Astra-Zeneca/medimmune: clinical trial BMS: advisory board, clinical trial Merck: advisory board, clinical trial, research funding Carla van Herpen Medical
More informationUnderstanding and overcoming immunoregulatory barriers within
Understanding and overcoming immunoregulatory barriers within the tumor microenvironment Thomas F. Gajewski, M.D., Ph.D. Professor, Departments of Pathology and Medicine Program Leader, Immunology and
More informationAdvances in Cancer Immunotherapy for Solid Tumors Expert Perspectives on The New Data Sunday, June 5, 2016
Advances in Cancer Immunotherapy for Solid Tumors Expert Perspectives on The New Data Sunday, June 5, 2016 Supported by an independent educational grant from AstraZeneca Not an official event of the 2016
More informationMelanoma, o status da imunoterapia e o futuro próximo
III International Symposium on Immuno-Oncology Saturday, October 7 th 9:3 1: am Melanoma, o status da imunoterapia e o futuro próximo Antoni Ribas, M.D., Ph.D. Professor of Medicine, Surgery, Molecular
More informationTumor Immunology. Wirsma Arif Harahap Surgical Oncology Consultant
Tumor Immunology Wirsma Arif Harahap Surgical Oncology Consultant 1) Immune responses that develop to cancer cells 2) Escape of cancer cells 3) Therapies: clinical and experimental Cancer cells can be
More informationImmunotherapy in breast cancer. Carmen Criscitiello, MD, PhD European Institute of Oncology Milan, Italy
Immunotherapy in breast cancer Carmen Criscitiello, MD, PhD European Institute of Oncology Milan, Italy Outline Rational for immune-based therapy in breast cancer Immunogenic chemotherapy Targeting immune
More informationAccepted Manuscript. Tumour Review. Resistance to PD1/PDL1 checkpoint inhibition
Accepted Manuscript Tumour Review Resistance to PD1/PDL1 checkpoint inhibition Jake S. O Donnell, Georgina V. Long, Richard A. Scolyer, Michele W. L. Teng, Mark J. Smyth PII: S0305-7372(16)30132-3 DOI:
More informationImmunotherapy in head and neck cancer and MSI in solid tumors
Immunotherapy in head and neck cancer and MSI in solid tumors Brian Hunis, MD, MBA Associate Medical Director, Memorial Cancer Institute. Hollywood, FL »No disclosures Objectives»Discuss the role of immunology
More informationUpdates in Immunotherapy for Urothelial Carcinoma
Updates in Immunotherapy for Urothelial Carcinoma Andrew J Armstrong MD ScM FACP DUA 2018 Copyright 2006 SciMed. Talk Outline Immunotherapy progress in 2017: 5 new approved PD-1/PD-L1 inhibitory agents
More informationCytokines: Interferons, Interleukins and Beyond. Michael B. Atkins, MD Georgetown-Lombardi Comprehensive Cancer Center
Cytokines: Interferons, Interleukins and Beyond Michael B. Atkins, MD Georgetown-Lombardi Comprehensive Cancer Center Disclosures Advisory Boards: Bristol-Myers Squibb,Amgen, Novartis, Alkermes, Infinity,
More informationEmerging Concepts of Cancer Immunotherapy
Emerging Concepts of Cancer Immunotherapy Jeffrey Schlom, Ph.D. Laboratory of Tumor Immunology and Biology (LTIB) Center for Cancer Research National Cancer Institute, NIH Immune Cell Infiltrate in Primary
More informationDaratumumab: Uncovering a novel mechanism of action for an approved antibody therapy
Daratumumab: Uncovering a novel mechanism of action for an approved antibody therapy Dr. Kate Sasser, PhD Corporate VP, Translational Research December 14 th, 2017 CD38 is ubiquitously expressed in Myeloma
More informationO DESAFIO DA INOVAÇÃO EM ONCOLOGIA EM PORTUGAL The Challenges of innovative oncology care in Portugal. Gabriela Sousa Oncologia Médica IPO Coimbra
O DESAFIO DA INOVAÇÃO EM ONCOLOGIA EM PORTUGAL The Challenges of innovative oncology care in Portugal Gabriela Sousa Oncologia Médica IPO Coimbra Incidência aumenta 3% ao ano Envelhecimento populacional
More informationThe Immune System. Innate. Adaptive. - skin, mucosal barriers - complement - neutrophils, NK cells, mast cells, basophils, eosinophils
Objectives - explain the rationale behind cellular adoptive immunotherapy - describe methods of improving cellular adoptive immunotherapy - identify mechanisms of tumor escape from cellular adoptive immunotherapy
More informationRenal Cell Carcinoma: Systemic Therapy Progress and Promise
Renal Cell Carcinoma: Systemic Therapy Progress and Promise Michael B. Atkins, M.D. Deputy Director, Lombardi Comprehensive Cancer Ctr Georgetown University Medical Center Everolimus Rini, Campbell, Escudier.
More informationPost-ASCO Immunotherapy Highlights (Part 2): Biomarkers for Immunotherapy
Post-ASCO Immunotherapy Highlights (Part 2): Biomarkers for Immunotherapy Lee S. Schwartzberg, MD, FACP Chief, Division of Hematology Oncology; Professor of Medicine, The University of Tennessee; The West
More informationImmune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment
Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment 1 Introductions Peter Langecker, MD, PhD Executive Medical Director, Global Oncology Clinipace Worldwide Mark Shapiro Vice President
More informationPredictive Biomarkers for Pembrolizumab. Eric H. Rubin, M.D.
Predictive Biomarkers for Pembrolizumab Eric H. Rubin, M.D. PD-1 and PD-L1/L2 Pathway PD-1 is an immune checkpoint receptor Binding of PD-1 by its ligands PD-L1 or PD-L2 leads to downregulation of T-cell
More informationTHE ROLE OF TARGETED THERAPY AND IMMUNOTHERAPY IN THE TREATMENT OF ADVANCED CERVIX CANCER
Gynecologic Cancer InterGroup Cervix Cancer Research Network THE ROLE OF TARGETED THERAPY AND IMMUNOTHERAPY IN THE TREATMENT OF ADVANCED CERVIX CANCER Linda Mileshkin, Medical Oncologist Peter MacCallum
More information2/19/2018. The Immune System and Cancer. Fatal Melanoma Transferred in a Donated Kidney 16 years after Melanoma Surgery
F141: Advanced Melanoma: Mechanisms of Immune Therapies beyond Checkpoint blockade Delphine J. Lee, MD, PhD Chief and Program Director, Dermatology, Harbor UCLA Medical Center Principal Investigator, Los
More informationInternational Society of Breast Pathology. Immune Targeting in Breast Cancer. USCAP 2017 Annual Meeting
International Society of Breast Pathology USCAP 2017 Annual Meeting Immune Targeting in Breast Cancer Ashley Cimino-Mathews, MD Assistant Professor of Pathology and Oncology The Johns Hopkins Hospital
More informationRadiation Therapy and Immunotherapy: New Frontiers
Radiation Therapy and Immunotherapy: New Frontiers Nevada Oncology Society Fall Meeting November 16 th, 2017 Anshu K. Jain, MD Radiation Oncologist, Ashland Bellefonte Cancer Center Assistant Clinical
More informationImmunotherapy in non-small cell lung cancer
Immunotherapy in non-small cell lung cancer Geoffrey Peters and Thomas John Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia. Email: Geoffrey.peters@austin.org.au Abstract
More informationSUPPLEMENTARY INFORMATION
Table S1: Combination Immunotherapy: Small Molecules that Boost Immune Response in Combination with Other Agents Target Compound (MOA) NLG919 and indoximod 1- MT Combination Model Observation Reference
More informationNuovi approcci immunoterapici nel trattamento del Melanoma: Background immunologico.
Nuovi approcci immunoterapici nel trattamento del Melanoma: Background immunologico. Andrea Anichini Human Tumors Immunobiology Unit Dept. of Experimental Oncology and Molecular Medicine Immune checkpoint
More informationInmunoterapia en tumores digestivos no colorrectales
Inmunoterapia en tumores digestivos no colorrectales Santander, 13 de Julio del 2017 Maria Alsina, MD PhD Hospital Universitari Vall d Hebron Outline Introduction Hepatocarcinoma Pancreatic Cancer Gastric
More informationTumor Immunology: A Primer
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationImmuno-Oncology Therapies and Precision Medicine: Personal Tumor-Specific Neoantigen Prediction by Machine Learning
Immuno-Oncology Therapies and Precision Medicine: Personal Tumor-Specific Neoantigen Prediction by Machine Learning Yi-Hsiang Hsu, MD, SCD Sep 16, 2017 yihsianghsu@hsl.harvard.edu Director & Associate
More informationEl contexto molecular de la sobreexpresión de PD-L1 Esther Conde Gallego, MD, PhD
El contexto molecular de la sobreexpresión de PD-L1 Esther Conde Gallego, MD, PhD Laboratorio de Dianas Terapéuticas Hospital Universitario HM Sanchinarro Madrid, Spain Contents Background PD-L1 expression
More informationThe quest for the identification of the genetic determinants of cancer immune responsiveness
2015 Sidra Medical and Research Center The quest for the identification of the genetic determinants of cancer immune responsiveness Francesco M Marincola - Chief Research Officer Sidra Medical and Research
More informationUnderstanding Checkpoint Inhibitors: Approved Agents, Drugs in Development and Combination Strategies. Michael A. Curran, Ph.D.
Understanding Checkpoint Inhibitors: Approved Agents, Drugs in Development and Combination Strategies Michael A. Curran, Ph.D. MD Anderson Cancer Center Department of Immunology Disclosures I have research
More informationThe head and neck cancer immune landscape and its immunotherapeutic implications
The head and neck cancer immune landscape and its immunotherapeutic implications Rajarsi Mandal,, Timothy A. Chan, Luc G.T. Morris JCI Insight. 2016;1(17):e89829. https://doi.org/10.1172/jci.insight.89829.
More informationThe head and neck cancer immune landscape and its immunotherapeutic implications
The head and neck cancer immune landscape and its immunotherapeutic implications Rajarsi Mandal, 1,2,3 Yasin Şenbabaoğlu, 4 Alexis Desrichard, 1,3 Jonathan J. Havel, 1,3 Martin G. Dalin, 1,3 Nadeem Riaz,
More informationInnate Immunity, Inflammation and Cancer
Innate Immunity, Inflammation and Cancer Willem Overwijk, Ph.D. Melanoma Medical Oncology Center for Cancer Immunology Research MD Anderson Cancer Center, Houston, TX SITC/MDACC -6/14/2013 www.allthingsbeautiful.com
More informationCurrent practice, needs and future directions in immuno-oncology research testing
Current practice, needs and future directions in immuno-oncology research testing Jose Carlos Machado IPATIMUP - Porto, Portugal ESMO 2017- THERMO FISHER SCIENTIFIC SYMPOSIUM Immune Therapies are Revolutionizing
More informationEmerging Targets in Immunotherapy
Emerging Targets in Immunotherapy So Jin Shin, M.D. Department of Obstetrics and Gynecology, Keimyung University, School of Medicine, Daegu, Korea no-0ncology Todays is.. ancer Immunotherapy? nd immunotherapy
More informationNovel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates
Novel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates Christopher Turner, MD Vice President, Clinical Science 04 November 2016 Uveal Melanoma Celldex Pipeline CANDIDATE INDICATION Preclinical
More informationACE ImmunoID Biomarker Discovery Solutions ACE ImmunoID Platform for Tumor Immunogenomics
ACE ImmunoID Biomarker Discovery Solutions ACE ImmunoID Platform for Tumor Immunogenomics Precision Genomics for Immuno-Oncology Personalis, Inc. ACE ImmunoID When one biomarker doesn t tell the whole
More informationIMMUNOTARGET THERAPY: ASPETTI GENERALI
IMMUNOTARGET THERAPY: ASPETTI GENERALI Alessandro Minisini Dipartimento di Oncologia Azienda Ospedaliero Universitaria Udine Verona, 19 settembre 2015 HALLMARKS OF CANCER Douglas Hanahan, Robert A. Weinberg,
More informationThe Microbiome in Cancer Immunotherapy
The Microbiome in Cancer Immunotherapy Sandip Patel, MD Assistant Professor UCSD Center for Microbiome Innovation Co-Leader, Experimental Therapeutics (Phase 1) Deputy Director, San Diego Center for Precision
More informationGSK Oncology. Axel Hoos, MD, PhD Senior Vice President, Oncology R&D. March 8, 2017
GSK Oncology Axel Hoos, MD, PhD Senior Vice President, Oncology R&D March 8, 217 GSK pipeline Oncology R&D Strategy Maximizing survival through transformational medicines and combinations Cancer Epigenetics
More informationBiologic Basis of Immunotherapy in Lung Cancer
Biologic Basis of Immunotherapy in Lung Cancer Andrew R. Haas, MD, PhD Director, Interventional Pulmonary and Thoracic Oncology Perelman School of Medicine of the University of Pennsylvania Philadelphia,
More information